Dermapharm Holding SE
DUS:DMP

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
DUS:DMP
Watchlist
Price: 38.75 EUR -0.26% Market Closed
Market Cap: 4.1B EUR
Section:
 

Relative Value

The Relative Value of one DMP stock under the Base Case scenario is hidden EUR. Compared to the current market price of 38.75 EUR, Dermapharm Holding SE is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DMP Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
58
vs Industry
53
Median 3Y
1.8
Median 5Y
2
Industry
2.7
Forward
1.7
More Details
17.7
P/E
P/E
Price to Earnings
17.7
vs History
58
vs Industry
20
Median 3Y
18.8
Median 5Y
19
Industry
21.5
Forward
16.6
More Details
10
P/OCF
P/OCF
Price to OCF
10
vs History
46
vs Industry
35
Median 3Y
9.2
Median 5Y
10.2
Industry
16.7
More Details
19.1
P/FCFE
P/FCFE
Price to FCFE
19.1
vs History
47
vs Industry
13
Median 3Y
16.4
Median 5Y
19.6
Industry
23
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
76
vs Industry
20
Median 3Y
3.5
Median 5Y
4
Industry
2.3
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
52
vs Industry
42
Median 3Y
2.4
Median 5Y
2.6
Industry
2.9
Forward
2.4
More Details
3.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.7
vs History
61
vs Industry
49
Median 3Y
3.7
Median 5Y
4
Industry
5.6
More Details
9.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.4
vs History
36
vs Industry
33
Median 3Y
9.2
Median 5Y
9.4
Industry
13.2
Forward
8.6
More Details
13.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.1
vs History
46
vs Industry
30
Median 3Y
13
Median 5Y
13.2
Industry
16.6
Forward
12.1
More Details
13.8
EV/OCF
EV/OCF
Enterprise Value to OCF
13.8
vs History
46
vs Industry
28
Median 3Y
12.9
Median 5Y
14
Industry
15.8
More Details
17.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.3
vs History
44
vs Industry
24
Median 3Y
16
Median 5Y
17.4
Industry
19
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
58
vs Industry
42
Median 3Y
1.5
Median 5Y
1.8
Industry
2
More Details

Multiples Across Competitors

DMP Competitors Multiples
Dermapharm Holding SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Dermapharm Holding SE
DUS:DMP
2.1B EUR 1.8 17.7 9.4 13.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.9 36.9 39.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
497.1B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
211.6B GBP 4.9 30.3 108.4 158.7
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
263.1B USD 4.1 13.8 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14 9.8 11.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
DE
Dermapharm Holding SE
DUS:DMP
Average P/E: 23.5
17.7
10%
1.8
US
Eli Lilly and Co
NYSE:LLY
54.9
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Dermapharm Holding SE
DUS:DMP
Average EV/EBITDA: 400.6
9.4
5%
1.9
US
Eli Lilly and Co
NYSE:LLY
36.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
1%
9.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Dermapharm Holding SE
DUS:DMP
Average EV/EBIT: 1 713.3
13.1
5%
2.6
US
Eli Lilly and Co
NYSE:LLY
39.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4

See Also

Summary
DMP intrinsic value, competitors valuation, and company profile.
DCF Valuation
DMP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DMP stock valuation using valuation multiples.
Wall Street Estimates
DMP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DMP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.